Bristol-Myers Squibb Company

11/29/2021 | Press release | Distributed by Public on 11/29/2021 06:00

Bristol Myers Squibb’s Applications for Deucravacitinib for the Treatment of Moderate to Severe Plaque Psoriasis Accepted by U.S. Food and Drug Administration and Validated by[...]